Abstract
In the course of heart failure, plasmatic levels of Tumor Necrosis Factor-alpha (TNF-alpha) are high and are related to prognosis and mortality. Infliximab, a recombinant chimeric antibody anti-TNF-alpha, was used in heart failure with disappointing results, similar to those obtained with other biological drugs.The aim of this study was the echocardiographic evaluation of infliximab infusion in nine patients without cardiac pathologies. The findings demonstrate a reduction of sistolic function and a modification of diastolic function after infliximab infusion in patients without cardiopathy. This study confirms the protective role played by TNFalpha on the myocardium, as suggested by previous experimental studies.
Publication types
-
Comparative Study
-
Evaluation Study
MeSH terms
-
Adult
-
Animals
-
Anti-Inflammatory Agents / administration & dosage
-
Anti-Inflammatory Agents / therapeutic use*
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / therapeutic use*
-
Behcet Syndrome / drug therapy*
-
Crohn Disease / drug therapy*
-
Diastole / physiology
-
Disease Models, Animal
-
Echocardiography*
-
Echocardiography, Doppler
-
Female
-
Gastrointestinal Agents / administration & dosage
-
Gastrointestinal Agents / therapeutic use*
-
Heart Failure* / blood
-
Heart Failure* / diagnostic imaging
-
Heart Failure* / mortality
-
Heart Failure* / physiopathology
-
Humans
-
Infliximab
-
Male
-
Mice
-
Mice, Knockout
-
Middle Aged
-
Systole / physiology
-
Tumor Necrosis Factor-alpha / blood
Substances
-
Anti-Inflammatory Agents
-
Antibodies, Monoclonal
-
Gastrointestinal Agents
-
Tumor Necrosis Factor-alpha
-
Infliximab